Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Three off-the-shelf mRNA therapies join intismeran autogene.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
